Biopharmaceuticals company eXmoor Pharma has outlined its ambitious global growth strategy for the next 18 months during a visit from the Minister for Science Research and Innovation, George Freeman MP.
Unveiling its plans to be the flagship tenant-business at Bristol’s Patchway Trading estate, eXmoor CEO Angela Osborne met with George Freeman on Friday, June 10 and discussed the importance of Government support in creating a new South West regional cell and gene therapy manufacturing cluster.
The highlight of the ministerial visit was an opportunity to view development progress at the 6,000 square metre facility currently under construction on the outskirts of north Bristol in South Gloucestershire.
The new facility will house eXmoor’s Process Development (PD) and Good Manufacturing Practice (GMP) operations and is scheduled to be fully operational for manufacturing during summer 2023.
eXmoor’s investment in this new c.£50 million purpose-built facility was facilitated by funding from MVM Partners in 2021. The company is also working on expansion into the North American market and plans to grow its UK-based team from 60 people to 200.
On the day, Mr Freeman chaired a networking lunch for guests Teresina Pinnington and Jon Smythe from NHS Blood & Transplant; Professor Moin Saleem of Purespring Therapeutics; Councillor Toby Savage, leader of South Gloucestershire council; and Antony Merritt, representing the West of England Combined Authority.
eXmoor Pharma CEO Angela Osborne said: “It has been good to outline our future plans and discuss the role which government policy plays in helping companies like eXmoor to flourish on the global stage.
“We’re focused on accelerating the manufacturing journey from research to patients for our clients, to treat some of the world’s major healthcare issues.
“To do that we need to encourage new talent into the industry, have the right landscape for research and development, and be assured that Government policy supports this.
“Ultimately, the UK economy needs to establish a thriving advanced manufacturing footprint in this and similar industries across the country.”